Strategies for inhibitor treatment and costs in the short and long term: A critical evaluation of recent clinical studies

European Journal of Haematology

Volumn 94, Issue s77, 2015, Pages 30-37

  Baghaipour, Mohammad Reza ^a   Steen Carlsson, Katarina ^b,c  

^a Comprehensive Hemophilia Care Center ^*  (Iran)

^b LUND UNIVERSITY   (Sweden)

^c SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

Author keywords

Bypassing agents; Clinical studies; Costs; Haemophilia; Inhibitors

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; PROTHROMBIN COMPLEX CONCENTRATES;

ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL (TOPIC); ECONOMICS; HEALTH CARE COST; HEMOPHILIA A; HEMORRHAGE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; SEVERITY OF ILLNESS INDEX; TIME;

ANTIBODIES; BLOOD COAGULATION FACTORS; CLINICAL TRIALS AS TOPIC; FACTOR VIII; HEALTH CARE COSTS; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNE TOLERANCE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84920274917     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12499     Document Type: Review

References (15)

1. White G. Coagulation factors V and VIII: normal function and clinical disorders. In: Handin R, Lux S, Stossel T, eds. Blood Principles and Practice of Hematology. Philadelphia: Lippincott; 1995.
2. Zhou ZY, Hay JW. Efficacy of bypassing agents in patients with haemophilia and inhibitors: a systematic review and meta-analysis. Clin Ther 2012;34:434-45.
3. Jimenez-Yuste V, Núñez R, Romero JA, Montoro B, Espinós B. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain. Haemophilia 2013;19:841-6.
4. Salaj P, Penka M, Smejkal P, Geierova V, Ovesná P, Brabec P, Cetkovsky P, Kubes R, Mesterton J, Lindgren P. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic. Thromb Res 2012;129:e233-7.
5. Hay JW, Zhou ZY. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors. Haemophilia 2011;17:e969-74.
6. Ozelo MC, Villaça PR, De Almeida JO, Bueno TM, De Miranda PA, Hart WM, Karamalis M. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil. Haemophilia 2007;13:462-9.
7. Bonnet PO, Yoon BS, Wong WY, Boswell K, Ewenstein BM. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries. Haemophilia 2009;15:1083-9.
8. You CW, Lee SY, Park SK. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea. Haemophilia 2009;15:217-26.
9. Steen Carlsson K, Astermark J, Donfield S, Berntorp E. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. Thromb Haemost 2008;99:1060-7.
10. Putnam KG, Bohn RL, Ewenstein BM, Winkelmayer WC, Avorn J. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Haemophilia 2005;11:261-9.
11. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000;96:1698-702.
12. Knight C, Paisley S, Wight J, Jones ML. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003;9:521-40.
13. Auerswald G, von Depka Prondzinski M, Ehlken B, Kreuz W, Kurnik K, Lenk H, Scharrer I, Schramm W, Zimmermann R. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004;10:499-508.
14. Ullman M, Hoots WK. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors. Haemophilia 2006;12(Suppl. 6):74-9.
15. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.